Immunocore Holdings plc (NASDAQ:IMCR) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. raised its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 25.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 546,318 shares of the company’s stock after purchasing an additional 109,206 shares during the quarter. Principal Financial Group Inc. owned 1.09% of Immunocore worth $17,007,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Envestnet Asset Management Inc. grew its position in shares of Immunocore by 0.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company’s stock worth $2,392,000 after acquiring an additional 606 shares in the last quarter. Pier Capital LLC grew its position in shares of Immunocore by 1.4% in the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock worth $2,568,000 after acquiring an additional 1,174 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after acquiring an additional 1,461 shares in the last quarter. Assetmark Inc. grew its position in shares of Immunocore by 6.5% in the 3rd quarter. Assetmark Inc. now owns 30,555 shares of the company’s stock worth $951,000 after acquiring an additional 1,878 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Immunocore by 69.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IMCR. Guggenheim downgraded Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. UBS Group began coverage on Immunocore in a report on Thursday, October 24th. They issued a “sell” rating and a $24.00 price target on the stock. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $72.00 to $38.00 in a report on Monday, November 11th. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 target price (down previously from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Down 3.4 %

Shares of IMCR stock opened at $29.18 on Friday. Immunocore Holdings plc has a 1 year low of $27.69 and a 1 year high of $76.98. The stock has a market cap of $1.46 billion, a PE ratio of -30.72 and a beta of 0.73. The business’s fifty day moving average is $31.66 and its 200-day moving average is $34.30. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company had revenue of $80.25 million for the quarter, compared to analysts’ expectations of $78.94 million. During the same period last year, the firm earned ($0.59) EPS. The firm’s revenue for the quarter was up 23.7% on a year-over-year basis. Equities analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.